SHP2 is associated with different diseases, and its upregulation has been observed in various cancers (e.g., leukemia, lung and breast cancers, and neuroblastomas), which is the reason SHP2 inhibitors are investigated as a strategy for cancer therapy [38]. The gene discussed is PTPN11; the disease is cancer.